These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

317 related items for PubMed ID: 23535489

  • 1. Timed 25-foot walk: direct evidence that improving 20% or greater is clinically meaningful in MS.
    Hobart J, Blight AR, Goodman A, Lynn F, Putzki N.
    Neurology; 2013 Apr 16; 80(16):1509-17. PubMed ID: 23535489
    [Abstract] [Full Text] [Related]

  • 2. Minimally important clinical difference of the Timed 25-Foot Walk Test: results from a randomized controlled trial in patients with multiple sclerosis.
    Coleman CI, Sobieraj DM, Marinucci LN.
    Curr Med Res Opin; 2012 Jan 16; 28(1):49-56. PubMed ID: 22073939
    [Abstract] [Full Text] [Related]

  • 3. Prolonged-release fampridine in multiple sclerosis: Improved ambulation effected by changes in walking pattern.
    Zörner B, Filli L, Reuter K, Kapitza S, Lörincz L, Sutter T, Weller D, Farkas M, Easthope CS, Czaplinski A, Weller M, Linnebank M.
    Mult Scler; 2016 Oct 16; 22(11):1463-1475. PubMed ID: 26762672
    [Abstract] [Full Text] [Related]

  • 4. Dalfampridine improves walking speed, walking endurance, and community participation in veterans with multiple sclerosis: a longitudinal cohort study.
    Cameron MH, Fitzpatrick M, Overs S, Murchison C, Manning J, Whitham R.
    Mult Scler; 2014 May 16; 20(6):733-8. PubMed ID: 24099749
    [Abstract] [Full Text] [Related]

  • 5. Long-term safety and efficacy of dalfampridine for walking impairment in patients with multiple sclerosis: Results of open-label extensions of two Phase 3 clinical trials.
    Goodman AD, Bethoux F, Brown TR, Schapiro RT, Cohen R, Marinucci LN, Henney HR, Blight AR, MS-F203, MS-F204, and Extension Study Investigators.
    Mult Scler; 2015 Sep 16; 21(10):1322-31. PubMed ID: 25583832
    [Abstract] [Full Text] [Related]

  • 6. Fampridine response in MS patients with gait impairment in a real-world setting: Need for new response criteria?
    Rodriguez-Leal FA, Haase R, Thomas K, Eisele JC, Proschmann U, Schultheiss T, Kern R, Ziemssen T.
    Mult Scler; 2018 Sep 16; 24(10):1337-1346. PubMed ID: 28741976
    [Abstract] [Full Text] [Related]

  • 7. Estimation of the effect of dalfampridine-ER on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
    Limone BL, Sidovar MF, Coleman CI.
    Health Qual Life Outcomes; 2013 Jun 26; 11():105. PubMed ID: 23799913
    [Abstract] [Full Text] [Related]

  • 8. Assessment of Clinically Meaningful Improvements in Self-Reported Walking Ability in Participants with Multiple Sclerosis: Results from the Randomized, Double-Blind, Phase III ENHANCE Trial of Prolonged-Release Fampridine.
    Hobart J, Ziemssen T, Feys P, Linnebank M, Goodman AD, Farrell R, Hupperts R, Blight AR, Englishby V, McNeill M, Chang I, Lima G, Elkins J, ENHANCE study investigators.
    CNS Drugs; 2019 Jan 26; 33(1):61-79. PubMed ID: 30535670
    [Abstract] [Full Text] [Related]

  • 9. Evaluation of functional outcome measures after fampridine treatment in patients with multiple sclerosis - An interventional follow-up study.
    Skov CD, Sørensen CB, Thorning M, Lambertsen KL, Frich LH, Jensen HB, Holsgaard-Larsen A, Nielsen HH.
    Mult Scler Relat Disord; 2022 Oct 26; 66():104034. PubMed ID: 35843140
    [Abstract] [Full Text] [Related]

  • 10. Monitoring long-term efficacy of fampridine in gait-impaired patients with multiple sclerosis.
    Filli L, Zörner B, Kapitza S, Reuter K, Lörincz L, Weller D, Sutter T, Killeen T, Gruber P, Petersen JA, Weller M, Linnebank M.
    Neurology; 2017 Feb 28; 88(9):832-841. PubMed ID: 28148629
    [Abstract] [Full Text] [Related]

  • 11. Effects of Dalfampridine Extended-release Tablets on 6-minute Walk Distance in Patients With Multiple Sclerosis: A Post Hoc Analysis of a Double-blind, Placebo-controlled Trial.
    Applebee A, Goodman AD, Mayadev AS, Bethoux F, Goldman MD, Klingler M, Blight AR, Carrazana EJ.
    Clin Ther; 2015 Dec 01; 37(12):2780-7. PubMed ID: 26565077
    [Abstract] [Full Text] [Related]

  • 12. Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
    Brambilla L, Rossi Sebastiano D, Aquino D, Torri Clerici V, Brenna G, Moscatelli M, Frangiamore R, Giovannetti AM, Antozzi C, Mantegazza R, Franceschetti S, Bruzzone MG, Erbetta A, Confalonieri P.
    J Neurol Sci; 2016 Sep 15; 368():402-7. PubMed ID: 27538672
    [Abstract] [Full Text] [Related]

  • 13. Dalfampridine extended release: in multiple sclerosis.
    Chwieduk CM, Keating GM.
    CNS Drugs; 2010 Oct 15; 24(10):883-91. PubMed ID: 20839898
    [Abstract] [Full Text] [Related]

  • 14. A guide to treating gait impairment with prolonged-release fampridine (Fampyra®) in patients with multiple sclerosis.
    Ramió-Torrentà L, Álvarez-Cermeño JC, Arroyo R, Casanova-Estruch B, Fernández O, García-Merino JA, Hernández MA, Izquierdo G, Martínez-Yélamos S, Meca J, Moral E, Olascoaga J, Prieto JM, Saiz A.
    Neurologia (Engl Ed); 2018 Jun 15; 33(5):327-337. PubMed ID: 26873645
    [Abstract] [Full Text] [Related]

  • 15. Fampridine for gait imbalance in patients with multiple sclerosis (MS): a systematic review and meta-analysis.
    Ghorbanpour S, Rahimibarghani S, Rohani S, Rastkar M, Ghajarzadeh M.
    Neurol Sci; 2023 Sep 15; 44(9):3059-3069. PubMed ID: 37055710
    [Abstract] [Full Text] [Related]

  • 16. Cognitive processing speed has minimal influence on the construct validity of Multiple Sclerosis Walking Scale-12 scores.
    Motl RW, Cadavid D, Sandroff BM, Pilutti LA, Pula JH, Benedict RH.
    J Neurol Sci; 2013 Dec 15; 335(1-2):169-73. PubMed ID: 24104065
    [Abstract] [Full Text] [Related]

  • 17. Fampridine-induced changes in walking kinetics are associated with clinical improvements in patients with multiple sclerosis.
    Weller D, Lörincz L, Sutter T, Reuter K, Linnebank M, Weller M, Zörner B, Filli L.
    J Neurol Sci; 2020 Sep 15; 416():116978. PubMed ID: 32559515
    [Abstract] [Full Text] [Related]

  • 18. Clinical overview of dalfampridine: an agent with a novel mechanism of action to help with gait disturbances.
    Egeberg MD, Oh CY, Bainbridge JL.
    Clin Ther; 2012 Nov 15; 34(11):2185-94. PubMed ID: 23123001
    [Abstract] [Full Text] [Related]

  • 19. Validity of minimal clinically important difference values for the multiple sclerosis walking scale-12?
    Motl RW, Learmonth YC, Pilutti LA, Dlugonski D, Klaren R.
    Eur Neurol; 2014 Nov 15; 71(3-4):196-202. PubMed ID: 24457548
    [Abstract] [Full Text] [Related]

  • 20. Responder rates to fampridine differ between clinical subgroups of MS patients and patient reported outcome influences treatment decision making.
    van Munster CEP, Kaya L, Lam KH, Kalkers NF, Killestein J, Uitdehaag BMJ.
    Mult Scler Relat Disord; 2020 Feb 15; 38():101489. PubMed ID: 31731213
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.